


# Adaptation of a pharmaceutical technology activity to COVID-19 : experiment in a peripheral hospital center



C. Biasolo<sup>1</sup>, A. De Coucy<sup>1</sup>, C. Bédoucha<sup>1</sup>, M. Gayral<sup>1</sup>, A-C. Marion<sup>1</sup>  
(1) : Pharmacy of the Libourne Hospital Center

## Introduction

In the context of the COVID-19 epidemic, new treatment recommendations have been published by various learned companies and expert groups. Their objective is **to reduce the number and length of day hospital (DH) stays.**

**OBJECTIVE :** To Evaluate the adaptation of our teams to the health crisis

## Material and method

Period of the study : mid-March to the end of May 2020


Carrying out a literature review : targeting protocols to be spaced out and cures to be cancelled

1. Consultation with oncologists and haematologists doctors → development of protocols
2. Collaboration with home care (HC) → to promote the care of patients at home



## Results

At the hospital in Libourne = 76 chemotherapies are prepared per day



## Discussion

- An insignificant decrease in our activity during the epidemic
- A low number of additional patients taken care of by HC, but this has **set a momentum**

## Conclusion

The decrease in the number of cures made it possible to **lower the passage of patients** in DH, reducing the risk of contamination in this fragile patient population.

Protocol before COVID-19 crisis	Protocol after COVID-19 crisis	Number of patients	Number of cancelled cures
Durvalumab 10mg/kg interval : 15 days	Durvalumab 1500mg interval : 28 days	10	23
Pembrolizumab 200mg interval : 21 days	Pembrolizumab 400mg interval : 42 days	2	4
Nivolumab 3mg/kg interval : 15 days	Nivolumab 480mg interval : 28 days	2	7
Carfilzomib J1J2 J8J9 J15J16 J22J23 – Dexamethasone – Daratumumab interval : 28 days	Carfilzomib (cancellation J2 J9 J16 without dose adjustment) – Dexamethasone – Daratumumab interval : 28 days	1	12
Cetuximab 400mg/m <sup>2</sup> J1 then 250 mg/m <sup>2</sup> J8 J15 – Docetaxel 75mg/m <sup>2</sup> – Cisplatine 75mg/m <sup>2</sup> interval : 21 days	Cetuximab 500mg/m <sup>2</sup> J1 (cancellation J8 J15) – Docetaxel 50mg/m <sup>2</sup> – Cisplatine 50mg/m <sup>2</sup> interval : 15 days	1	2